BackgroundCardiomyopathy, a heart disease that arises from different etiologies, brings a huge healthcare burden to the global society. Identification of biomarkers can be very useful for early diagnosis of cardiomyopathy, interruption of the disease procession to heart failure, and decrement of the mortality. MethodsClinical cases of cardiomyopathy were screened out of independently investigations from the genomic database. Exploration of its whole transcription disorder pattern by WGCNA (Weighted Gene Co-expression Network Analysis) to discover the signature genes for different subtypes of cardiomyopathy. The hub genes and key pathways, which are correlated to cardiomyopathy traits, were identified through co-expression and protein-protein interaction (PPI) networks enrichment analysis. Discovered hub genes were blast through the Cardiovascular Disease Portal to verify functions related to human cardiomyopathies.ResultsThree common axes of signature genes were discovered for five subtypes of cardiomyopathy: 1) Four genes (MDM4, CFLAR, RPS6KB1, PKD1L2) were common for ischemic and ischemic cardiomyopathy subgroups; 2) Subtypes of cardiomyopathy (ischemic, post. partum, familiar and idiopathic) shared eight genes (MAPK1, MAPK11, MAPK14, LMNA, RAC1, PECAM1, XIAP, CREB1); 3) TFAM and RHEB were the common signature genes for subtypes of cardiomyopathy (viral, post. partum, familiar, and idiopathic). Major pathways enriched were including MAPK signaling pathway, the pathway of protein processing in endoplasmic reticulum, and pathway of regulatory actin cytoskeleton. Aberrant in these pathways caused disorders metabolic process and cellular malfunctions that generally contributes to cardiac dysregulation and functional relapse into cardiomyopathies.ConclusionThis study identified the key signaling pathways, functions and biological process related to cardiomyopathies and will give a light to better understand the molecular mechanism of processes of cardiomyopathies and figure out the rational clinical interference way to cure the patients. Therein, these novel signature genes may work as potential promising biomarkers for cardiomyopathy diagnosis, and will benefit for the better clinical diagnostics and outcome for patients with cardiomyopathies.